Abstracts

Antiviral Activity/Safety of a Second-Generation HIV-1 Maturation Inhibitor

Background: BMS-955176 is a 2nd-generation HIV-1 maturation inhibitor (MI). A 1st”‘generation MI (bevirimat) showed clinical efficacy in early-phase studies, but ~50% of subjects had reduced viral susceptibility associated with naturally occurring polymorphisms in Gag. We assessed BMS-955176 antiviral activity, safety, and exposure–response during 10 days of monotherapy in HIV-1, subtype B-infected subjects. Methods: AI468002 (NCT01803074)…

Untimed Drug Levels and Resistance in Patients Experiencing Low-Level HIV Viremia

Background: HIV resistance testing in HAART patients experiencing low-level viremia (LLV, 50-999 HIV-RNA copies/mL) predicts the risk of subsequent virologic failure (VF, ≥1000 copies/ml). Suboptimal plasma drug levels can arise as a result of poor adherence and/or pharmacokinetic issues. Here, our aim was to evaluate whether retrospective analysis of plasma levels also provides insight into…

Fitness Effects of Drug-Resistant Strains Across the United States HIV-1 Transmission Network

Background: Drug resistance associated mutations (DRAMs) can reduce the effectiveness of antiretrovirals (ARVs). DRAMs from multiple drug classes can have deleterious effects on intrahost viral fitness (replication) and may reduce transmissibility. We used genetic transmission network analysis to assess the effect of DRAMs on interhost viral fitness (transmission, or network links). Methods: We analyzed 66,235…

Innate Sensing of HIV-1 in Macrophages

Given the important role of cytosolic DNA in stimulating innate immune responses, there is an intense interest in defining the sensors of HIV DNA and the cellular mechanisms underlying subsequent induction of Interferon (IFN). The innate immune response is orchestrated in a complex manner where various pathogen recognition receptors scavenge for pathogen associated molecular patterns.…